On November 6, Insulet fell 5.84% in Regular Trading, trading at $146.505, with turnover of $19.7444 million.
The move followed a shift in focus from a recent third-quarter earnings beat and $1 billion buyback authorization toward valuation digestion, while a newly published analyst note said Insulet still looks attractively valued despite a more conservative fiscal 2027 revenue outlook.
Earlier this week, Insulet reported adjusted EPS of $1.99 on revenue of $842.0 million, both above consensus, and maintained its full-year adjusted EPS growth outlook of over 30%. The company also said it expects to repurchase about $400 million of shares in the fourth quarter. However, the latest analyst commentary pointed to tougher comparisons, less pricing benefit outside the US, and increased competition in 2027, even as it kept a constructive long-term view based on Omnipod's disposable pump design, pharmacy-channel position, and expansion opportunities in Type 1 and Type 2 diabetes.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments